Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

39.67 +0.59 (+1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims for European launch in 2025 
Via Benzinga
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook. 
Via Benzinga
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
From Genentech
Via Business Wire
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis. 
Via Benzinga
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
The companies both have drugs that treat relapsing forms of multiple sclerosis. 
Via Investor's Business Daily
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
Via Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
Via The Motley Fool
Topics ETFs
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
Via Investor's Business Daily
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights. 
Via Benzinga
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
From Genentech
Via Business Wire
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events. 
Via Benzinga
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
From Genentech
Via Business Wire
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Exposures Product Safety
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
From Genentech
Via Business Wire
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
From Genentech
Via Business Wire
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. 
Via Benzinga
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. 
Via Benzinga
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
Exposures Product Safety
Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint
The company is also facing off with biosimilars for standard Eylea and competition with Roche. 
Via Investor's Business Daily
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.